Evidence map›Paper›PMID 37445731›Full record

ArticleInternational journal of molecular sciences2023

The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells.

Davide Capoferri, Paola Chiodelli, Marzia Corli, Mirella Belleri, Elisa Scalvini, Luca Mignani, Jessica Guerra, Elisabetta Grillo, Veronica De Giorgis, Marcello Manfredi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Davide CapoferriUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-1251-8136
Paola ChiodelliUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Marzia CorliUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Mirella BelleriUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Elisa ScalviniUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Luca MignaniUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Jessica GuerraUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
Elisabetta GrilloUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-8403-0607
Veronica De GiorgisDepartment of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Marcello ManfrediDepartment of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.
Marco PrestaUnit of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-4398-8376
University of Brescia · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITConsorzio Interuniversitario per le Biotecnologie · IT

Funding

Department of Excellence - DIMET - Università del Piemonte Orientale AGING ProjectItalian Association for Cancer Research IG Grant n°18493
6 · The paper itself

Abstract

β-Galactosylceramidase (GALC) is a lysosomal enzyme involved in sphingolipid metabolism by removing β-galactosyl moieties from β-galactosylceramide and β-galactosylsphingosine. Previous observations have shown that GALC may exert pro-oncogenic functions in melanoma and

Indexed as

Melanoma, ExperimentalSkin NeoplasmsAnimalsCell Line, TumorChromatography, LiquidCutaneous Malignant MelanomaGalactosylceramidaseHumansMiceMutationProteomicsProto-Oncogene Proteins B-rafSphingolipidsTandem Mass SpectrometryBRAF protein, humanGalactosylceramidaseProto-Oncogene Proteins B-rafSphingolipidsmelanomaproteomicsβ-galactosylceramidase

Identifiers

PMID37445731
PMCPMC10342161
OpenAlexW4382068521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.